Oova Pricing Analysis & Total Cost: Is It Worth It for Fertility Hormone Tracking?

What Oova Actually Costs: The Real Number After Year One

The headline device price is not your true cost. Over 12 months of consistent use, most women spend between $787 and $1,147 on Oova when you add the starter kit to 11 months of refill strips. That figure assumes one strip pack per cycle and no repeat testing within a cycle, which is optimistic for women with irregular cycles or PCOS.

Oova sells its system as a one-time hardware purchase paired with ongoing consumable strip subscriptions. The reader device uses a smartphone camera and proprietary app to quantify hormone concentrations from the strip, rather than giving you a simple positive/negative line. That quantitative output is the core selling point: instead of "LH surge detected," you see an actual concentration in mIU/mL, plotted against your personal baseline across your cycle.

What the Kit Includes

The standard starter bundle (as listed on Oova's website, January 2025) includes:

• One reusable Oova reader attachment for your smartphone
• One cycle's worth of hormone test strips (typically 15-20 strips per pack, covering LH, FSH, and PdG)
• Access to the Oova app with personalized tracking and cycle analysis

Replacement strip packs are sold separately. Oova has offered subscription pricing at a modest discount (approximately 10-15% off single-cycle pack pricing) if you commit to auto-ship.

Where the Costs Add Up

Women with PCOS, perimenopause, or unexplained infertility often need more strips per cycle because their cycles are longer or their LH patterns are atypical. Research published in Fertility and Sterility shows that women with PCOS have significantly higher baseline LH and more frequent LH pulses than ovulatory controls, which means a single strip pack may undercount your actual testing needs. Budget for 1.5 to 2 packs per cycle if your cycles exceed 35 days or are highly irregular.

Additional costs not included in Oova's advertised price:

• Clinical interpretation: Oova does not provide a clinician in the device cost. If you need a reproductive endocrinologist or NP to interpret your quantitative results, that is a separate telehealth visit ($75-$200+ depending on platform and insurance).
• Repeat cycle testing: If you are using Oova to confirm ovulation confirmation via PdG after an IUI or timed intercourse, you may run more strips in the luteal phase than the pack anticipates.
• Shipping: Subscription shipping is often free, but one-off strip purchases may carry a fee.

What Oova Measures and Why It Matters for Women

Oova tracks three hormones from urine, and each one tells a different part of your reproductive story.

LH (Luteinizing Hormone)

LH surges 24-36 hours before ovulation. Standard OPKs detect the surge qualitatively (a line darker than the control). Oova plots your daily LH concentration numerically, which theoretically helps you distinguish a true pre-ovulatory surge from the background LH fluctuations that are common in PCOS. Women with PCOS can have tonic LH elevations that falsely trigger standard OPK positives, so a numeric trend may offer more interpretive value than a binary result.

FSH (Follicle-Stimulating Hormone)

Tracking FSH from urine is less standard than serum FSH. Oova measures urinary FSH as a proxy for ovarian reserve signaling and cycle day-2/3 FSH levels, which clinically correlate with ovarian reserve when measured in blood. Serum FSH on cycle day 3 above 10 IU/L is associated with diminished ovarian reserve per ASRM guidelines, and Oova's app attempts to translate urinary FSH into a comparable signal. Independent validation of that translation in a peer-reviewed trial has not been published as of this writing.

PdG (Pregnanediol Glucuronide)

PdG is the urinary metabolite of progesterone. Serum progesterone >3 ng/mL on day 21 of a 28-day cycle is the conventional confirmation of ovulation. A 2019 study in Clinical Chemistry and Laboratory Medicine confirmed that urinary PdG correlates with serum progesterone and can confirm ovulation with good sensitivity. Oova uses PdG to confirm that ovulation actually occurred, not just that an LH surge was detected, which is a meaningful clinical addition over basic OPKs.

Oova for PCOS: Does the Extra Data Justify the Extra Cost?

PCOS is the most common endocrine disorder in reproductive-age women, affecting approximately 1 in 10 women of reproductive age according to the CDC. Standard OPKs are notoriously unreliable for women with PCOS because of chronically elevated or erratically fluctuating LH. The quantitative LH trend that Oova provides is genuinely more informative for this population.

If you have PCOS and are trying to conceive, Oova's numeric LH tracking paired with PdG confirmation of ovulation gives you a more complete picture than a $12 drugstore OPK strip kit. The question is whether it is complete enough to replace a serum progesterone draw ordered by your OB-GYN or RE, and the honest answer is: probably not as a standalone. Oova should be used alongside, not instead of, periodic serum labs if you are working with a reproductive endocrinologist.

A practical framework for PCOS users:

| Your situation | Oova value | Recommendation | |---|---|---| | Irregular cycles, trying to conceive, no RE yet | High | Use Oova to identify LH patterns; bring trend data to first RE consult | | Active IUI or IVF cycle | Low to moderate | Your clinic monitors serum LH/E2/P4; Oova adds limited clinical value | | PCOS, not TTC, tracking for cycle awareness | Moderate | Less expensive cycle apps with basal body temperature may suffice | | Anovulatory PCOS confirmed by RE | Low | Serum monitoring under clinical care is more accurate |

Oova for Perimenopause: Hormone Tracking When Cycles Become Unpredictable

Perimenopause, the transition typically beginning in the mid-to-late 40s, is defined by cycle variability of 7 or more days from your normal cycle length in the preceding 10 cycles, per the STRAW+10 staging criteria. FSH rises and estradiol fluctuates erratically during this transition. Tracking FSH trends at home is appealing to women trying to understand where they are in this transition.

Oova markets partly to this audience, and there is real logic to it. But several caveats apply:

• Urinary FSH can fluctuate day to day even in a single woman, so a single reading is not diagnostically reliable.
• The Menopause Society (formerly NAMS) states that FSH levels alone cannot reliably confirm or exclude perimenopause, particularly in women still having cycles.
• If you are perimenopausal and considering hormone therapy, your clinician will want serum FSH and estradiol, not urinary proxy measurements.

Oova may be useful for perimenopausal women as a tracking tool to spot trends over time, particularly if you are interested in whether you are still ovulating in your 40s. It is not a substitute for the serum workup that informs HRT decisions.

A Note on Contraception During Perimenopause

Pregnancy remains possible during perimenopause until you have had 12 consecutive months without a period (the clinical definition of menopause, per ACOG Practice Bulletin No. 141). Oova is a monitoring tool, not a contraceptive. Do not use it to time unprotected intercourse for pregnancy prevention.

Pregnancy and Lactation: When to Stop Using Oova

Oova is a diagnostic monitoring device, not a drug, so the pregnancy safety question is different from a medication risk assessment. There is no pharmacological exposure risk to the fetus or nursing infant.

What you should know:

• Oova is designed for pre-conception hormone monitoring. Once pregnancy is confirmed, the device has no validated clinical use and should be discontinued.
• The strips are not validated to interpret hormone levels during pregnancy, when HCG, progesterone, and LH physiology are entirely different from the non-pregnant cycle.
• If you are lactating, ovulation may return unpredictably, particularly after the first 6 months postpartum or when breastfeeding frequency decreases. Lactational amenorrhea provides approximately 98% contraceptive protection only when specific criteria are met: the infant is under 6 months old, the mother is fully breastfeeding, and menses have not returned, per the WHO. If you are postpartum and trying to understand whether your cycles are returning, Oova could theoretically help track LH and PdG, but this use has not been specifically validated by the company or in published literature.

Is Oova Legit? Evaluating the Evidence Base

This is the question that deserves a direct answer rather than a marketing summary.

FDA Clearance Status

As of January 2025, Oova's test strips are marketed as LDTs (laboratory-developed tests) or consumer diagnostics. The device is not FDA-cleared as a prescription fertility monitor in the same regulatory category as, for example, the Clearblue Advanced Fertility Monitor. Consumers should be aware that the regulatory pathway for direct-to-consumer hormone quantification devices is still evolving. Oova has stated internally that it operates within FDA enforcement discretion for consumer wellness devices. This does not mean the device is unsafe, but it does mean independent analytical validation data is limited in the public domain.

Published Accuracy Data

Oova published a company-sponsored analytical validation study showing strong correlation between Oova strip readings and reference laboratory values for LH and PdG. A 2022 study in PLOS ONE co-authored with Oova researchers reported high concordance for ovulation detection compared to serum reference standards. This is encouraging, but the study was conducted by parties with commercial interests, and no large-scale independent replication has appeared in peer-reviewed literature as of this writing. That evidence gap matters, and you should factor it into your decision.

User Experience Data

Oova has an active user base with generally positive reviews on consumer platforms. Common themes in genuine user reviews:

• The app interface and quantitative graphs are appreciated by users who want more data than a simple positive/negative.
• Strip accuracy has been questioned by some users when results diverge from their clinic serum labs.
• Customer service responsiveness has been inconsistent based on review patterns across multiple platforms (not a clinical concern, but a practical one).

Oova vs. Alternatives: A Practical Comparison

Several devices occupy the same space. Here is a direct comparison:

| Device | Device cost | Monthly consumable | Hormones tracked | Quantitative output | Independent validation | |---|---|---|---|---|---| | Oova | $199-$249 | $49-$79 | LH, FSH, PdG | Yes | Limited (company-sponsored) | | Mira Fertility Plus | $199 | $45-$60 | LH, E3G, PdG, FSH | Yes | Limited (company-sponsored) | | Clearblue Advanced Connected | $149 | $30-$50 | LH, E3G | No (semi-quantitative) | Moderate (some independent data) | | Standard OPK strips (drugstore) | $0 (no device) | $12-$20 | LH only | No | Extensive | | Serum lab panel (RE or OB-GYN) | $0-$150 co-pay | Per visit | All hormones, precise | Gold standard | Extensive |

Mira is the most direct Oova competitor. Both provide quantitative urinary hormone readings via a smartphone-connected device at similar price points. Mira also tracks estrogen (E3G), which Oova does not currently include in its standard panel. If estrogen trajectory matters to you (relevant in perimenopause monitoring and cycle prediction), Mira's broader panel may be worth comparing.

ASRM's committee opinion on ovulation prediction notes that no single urinary test has been shown superior to a comprehensive serum hormone panel interpreted by a reproductive endocrinologist, which is worth keeping in mind when evaluating any at-home device.

Who This Is Right for and Who Should Skip It

Good fit: you will likely get value from Oova if you are...

• A woman in her reproductive years trying to conceive, with irregular cycles, who wants more granular data than a standard OPK provides
• A woman with suspected or confirmed PCOS using LH tracking to identify ovulation patterns before or between clinical appointments
• A perimenopausal woman in her 40s who wants to track FSH trends over time alongside other cycle data, with the understanding that this is supplementary information
• Someone who has already completed a baseline serum workup with a clinician and wants ongoing home monitoring between appointments

Not a good fit: skip Oova if you are...

• Currently undergoing monitored IUI or IVF cycles (your clinic's serum monitoring supersedes at-home devices)
• Pregnant or recently postpartum (the device has no validated utility in these states)
• Looking for a contraception aid (Oova is not validated as a contraceptive method)
• Working with a tight budget and have not yet had a basic serum FSH, LH, and AMH panel drawn (a one-time serum panel gives you more precise baseline data than months of urinary monitoring)
• Someone who has had no clinical evaluation of infertility after 12 months of trying to conceive under age 35, or 6 months of trying over age 35. ACOG recommends referral to a reproductive specialist at these thresholds, and a device purchase should not replace that referral.

The Evidence Gap: What We Still Do Not Know

Women have been historically under-represented in diagnostic device validation studies, and fertility monitors are no exception. Nearly all the published accuracy data for urinary LH and PdG monitors comes from small, selected study populations. A 2021 systematic review in Human Reproduction Update found that evidence quality for consumer fertility monitors was generally low to moderate, with most studies having small sample sizes and high risk of commercial bias. That review did not specifically evaluate Oova by name, but the methodological concerns apply to the category.

What this means practically: the numeric LH and PdG values Oova gives you are likely directionally accurate. Whether they are precise enough to replace serum values in clinical decision-making is unproven. Use them as trend data, not as diagnostic anchors.

Practical Advice Before You Buy

Before spending $200 on a device and committing to a monthly strip budget, take these steps:

1. Ask your OB-GYN or NP to order a cycle day-3 serum FSH, LH, estradiol, and AMH. This one-time panel costs $50-$150 with insurance and gives you a clinically validated baseline. You will interpret Oova's urinary readings far more accurately if you know your serum baseline.
2. If you have PCOS, confirm whether you are ovulatory or anovulatory before investing in a cycle-tracking device. The Rotterdam criteria require two of three features for PCOS diagnosis: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound, per the ESHRE/ASRM consensus. If you are anovulatory, tracking LH surges that may not lead to ovulation produces data with limited actionability.
3. Check whether your FSA or HSA covers fertility monitoring devices. Many do. Oova strips have been listed as FSA-eligible on FSA Store, which reduces your effective out-of-pocket cost by 20-37% depending on your tax bracket.
4. Start with one cycle's worth of strips before committing to an auto-ship subscription. Assess whether the data integrates usefully with your clinical care before locking in.

ASRM's most recent committee opinion on optimizing natural fertility recommends that couples use ovulation prediction methods to time intercourse, but explicitly notes that there is no evidence that using any specific monitor improves live birth rates over standard timed intercourse guided by cycle history. That is not a reason to avoid Oova, but it is context worth having before you spend $1,000 over the next year.